Baroda BNP Paribas Large & Mid Cap Fund
(An open ended scheme investing in both
large cap and mid cap stocks)
Baroda BNP Paribas Large & Mid Cap Fund
(An open ended scheme investing in both
large cap and mid cap stocks)
February 2025

February 2025


Investment Objective

The primary objective of the Scheme is to seek long term capital growth through investments in both large cap and mid cap stocks. However, there is no assurance that the investment objective of the Scheme will be achieved

NAV Details (As on February 28, 2025)
Regular Plan - IDCW Option : ₹18.3707
Regular Plan - Growth Option : ₹23.2350
Direct Plan - IDCW Option : ₹20.8795
Direct Plan - Growth Option : ₹24.8422
Benchmark Index (Tier 1)

BSE 250 Large & Mid Cap TRI

Date of Allotment

September 04, 2020

Fund Manager
Fund Manager Managing fund since Experience
Mr. Sanjay Chawla 04-Sep-20 33 years
Mr. Kirtan Mehta 01-Jan-25 26 years
Load Structure

Exit Load: • If units are redeemed up to 10% of the units held on or before 365 days from the date of allotment - Nil • If units are redeemed over and above the 10% limit on or before 365 days from the date of allotment - 1% of the applicable Net Asset Value (NAV) • If units of scheme are redeemed after 365 days from the date of allotment - Nil.
For detailed load structure please refer Scheme Information Document.


Lumpsum Details

Minimum Amount: Lumpsum investment:
₹ 5,000 and in multiples of ₹ 1 thereafter.
Minimum Additional Application Amount:₹ 1,000 and in multiples of ₹ 1 thereafter.


Monthly AAUM## As on February 28, 2025 : ₹ 1,401.95 Crores
AUM## As on February 28, 2025 : ₹ 1,330.83 Crores

## including inter-scheme Investments, if any, by other schemes of Baroda BNP Paribas Mutual Fund, as may be applicable

EQUITY HOLDINGS% of Net Assets
Banks 19.01%
HDFC Bank Limited 7.16%
ICICI Bank Limited 5.43%
The Federal Bank Limited 3.07%
Bank of Baroda 2.07%
AU Small Finance Bank Limited 1.28%
Finance 8.88%
Shriram Finance Limited 3.25%
CRISIL Limited 3.05%
PNB Housing Finance Limited 2.58%
Pharmaceuticals & Biotechnology 8.54%
Concord Biotech Limited 2.02%
Ajanta Pharma Limited 1.96%
Alkem Laboratories Limited 1.92%
Divi's Laboratories Limited 1.44%
Sun Pharmaceutical Industries Limited 1.20%
IT - Software 7.26%
Infosys Limited 3.55%
Wipro Limited 1.88%
Tata Consultancy Services Limited 1.83%
Petroleum Products 7.17%
Reliance Industries Limited 4.96%
Hindustan Petroleum Corporation Limited 2.21%
Consumer Durables 5.56%
Dixon Technologies (India) Limited 3.14%
Blue Star Limited 2.42%
Retailing 3.90%
Info Edge (India) Limited 1.58%
Zomato Limited 1.25%
FSN E-Commerce Ventures Limited 1.07%
Financial Technology (Fintech) 3.30%
PB Fintech Limited 3.30%
Insurance 3.08%
Max Financial Services Limited 2.06%
ICICI Lombard General Insurance Company Limited 1.02%
Electrical Equipment 2.72%
GE Vernova T&D India Limited 1.79%
ABB India Limited 0.93%
Power 2.69%
Power Grid Corporation of India Limited 1.51%
NTPC Green Energy Limited 1.18%
Telecom - Services 2.65%
Bharti Airtel Limited 2.65%
Textiles & Apparels 2.44%
Page Industries Limited 2.44%
Construction 2.38%
Larsen & Toubro Limited 1.36%
Afcons Infrastructure Limited 1.02%
Leisure Services 2.02%
The Indian Hotels Company Limited 2.02%
Capital Markets 1.89%
Computer Age Management Services Limited 1.89%
Industrial Manufacturing 1.86%
Kaynes Technology India Limited 1.86%
Oil 1.74%
Oil India Limited 1.74%
Healthcare Services 1.38%
Jupiter Life Line Hospitals Limited 1.38%
Auto Components 1.23%
ZF Commercial Vehicle Control Systems India Limited 1.23%
Agricultural, Commercial & Construction Vehicles 1.19%
Escorts Kubota Limited 1.19%
Agricultural Food & other Products 1.00%
Adani Wilmar Limited 1.00%
Cement & Cement Products 0.99%
JK Cement Limited 0.99%
LESS THAN 0.75% EXPOSURE 0.50%
TOTAL EQUITY HOLDING 93.38%
Total Fixed Income Holdings 6.62%
TREPS, Cash & Other Net Current Assets 6.62%
GRAND TOTAL 100.00%

Investment in Top 10 scrips constitutes 39.56% of the portfolio


For SIP Performance please click here

For Scheme Performance please click here

The scheme currently does not have a Distribution track record.


Pursuant to distribution under Income Distribution cum Capital Withdrawal (‘IDCW’) option, NAV of the IDCW option of the scheme(s) would fall to the extent of payout and statutory levy (if applicable). The amounts under IDCW options can be distributed out of investors capital (Equalization Reserve), which is part of sale price that represents realized gains. Past performance may or may not be sustained in future. The above stated distribution rate per unit is net distribution rate after deducting applicable taxes. The above distribution rates are on face value of ₹ 10 per unit.

TER - Regular Plan (%) 2.11%
TER - Direct Plan (%) 0.83%
Portfolio Turnover Ratio 0.88
Standard Deviation* 15.59%
Beta* 1.01
Sharpe Ratio* 0.50
Sharpe Ratio (annualised), Standard Deviation (annualised) and Beta are based on last 36 monthly data points.

The risk free rate of return considered for calculation of Sharpe ratio is 6.40%, as per 1 day MIBOR rate on the lastbusiness day of the month.

No of Stocks 44
Portfolio RoE (%) 16.16
EPS Growth (%) 32.75

This product is suitable for investors who are seeking*:

➤ Capital appreciation over long term.
➤ Investment predominantly in equity and equity related instruments of large and midcap stocks.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

Scheme Riskometer^^
Investors understand that their principal will be at Very High risk


Benchmark (Tier 1) Riskometer^
Benchmark riskometer is at Very High risk


^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (BSE 250 Large & Mid Cap TRI): basis it’s constituents; As on February 28, 2025

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.
For complete portfolio, kindly refer the website https://www.barodabnpparibasmf.in/